NAs
Phase 2Small molecule
NAs is one of 96 small molecule programs targeting Chronic Hepatitis b. It is currently in Phase 2.
3
Indications
7
Total Trials
7
Active Trials
95
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
74 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Tyzeka
NovartisApproved
Actos
TakedaApproved
Vemlidy
GileadApproved
Emtriva
GileadApproved
Aldactone
PfizerApproved
Cymbalta
Jazz PharmaceuticalsApproved
Jardiance
Boehringer IngelheimApproved
Esmeron
FFresenius Kabi USA, LLC
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Bumex
VValidus Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis b4 trials
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT07845058·1,200 enrolled
PD-1antibody1 trial
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Active, not recruiting·—·N/A·NCT06357806·45 enrolled
Combination Therapy1 trial
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
Recruiting·—·N/A·NCT06457477·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NAs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAusper Biopharma Co., Ltd.